Filing Details

Accession Number:
0001127602-14-004590
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-05 16:58:28
Reporting Period:
2014-02-03
Filing Date:
2014-02-05
Accepted Time:
2014-02-05 16:58:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1145197 Insulet Corp PODD Surgical & Medical Instruments & Apparatus (3841) 043523891
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1470548 Peter Devlin C/O Insulet Corporation
9 Oak Park Drive
Bedford MA 01730
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-02-03 30,000 $8.30 93,081 No 4 M Direct
Common Stock Disposition 2014-02-03 30,000 $42.82 63,081 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2014-02-03 30,000 $0.00 30,000 $8.30
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
30,000 2019-08-17 No 4 M Direct
Footnotes
  1. Includes 6,667 restricted stock units granted on March 1, 2010 which vest on March 1, 2014; 16,500 restricted stock units granted on April 1, 2012 which vest one-third of the total units on April 1, 2014, one-third of the total units on April 1, 2015 and one-third of the total units on April 1, 2016; and 16,800 restricted stock units granted on March 1, 2013 which vest one-quarter of the total units on March 1, 2014, one-quarter of the total units on March 1, 2015, one-quarter of the total units on March 1, 2016 and one-quarter of the total units on March 1, 2017. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2013.
  3. The price reported represents the weighted average sale price of shares sold. The shares were sold at varing prices in the range of $42.04 to $43.49. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
  4. This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.